Key facts
- Yunu’s last known valuation is $45.0M (Apr 2025).
- It has raised $14.3M; the latest was Early Stage VC ($11.3M) in Apr 2025.
- Notable investors include Spring Mountain Capital, First Analysis.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Yunu
- ·The full record, as it builds
Funding rounds
No funding rounds for Yunu are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yunu
Developer of a clinical trial imaging platform designed to streamline oncology trials by improving speed, accuracy, and regulatory compliance. The company's platform offers automated workflows, real-time dashboards, protocol-guided imaging assessments, centralized data management, and integrated quality control, enabling sponsors, CROs, and cancer centers to conduct trials efficiently, reduce manual workload, ensure compliance, and quality imaging data.
- Sector
- Healthcare
- HQ
- Cary, NC, United States
- Founded
- 2022
- Employees
- 43
- Website
- yunu.io/
- Ownership
- Privately Held (backing)
Yunu doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yunu shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yunu in its N-PORT filings yet. We sweep new filings monthly.